OXB — Oxford BioMedica Share Price
Last trade - 00:00- £316.93m
- £368.48m
- £128.80m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 5.56 | ||
| Price to Tang. Book | 11.39 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.46 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -22.72% | ||
| Return on Equity | -65.91% | ||
| Operating Margin | -30.57% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | 87.73 | 142.8 | 139.99 | 89.54 | 128.8 | 163.87 | 210.08 | 14.99% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Oxford Biomedica PLC is a contract development and manufacturing organization (CDMO) in cell and gene therapy. It provides viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. It offers several technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the Tetravecta system), dual plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines. It has bioprocessing and manufacturing facilities across Oxfordshire, United Kingdom, Lyon and Strasbourg, France and near Boston, MA, United Sates. Its Platform segment is involved in bioprocessing and process development activities undertaken for third parties. Its Viral Vector includes LentiVector platform, inAAVate platform, and Other Viral Vectors. Its LentiVector platform technology is an advanced lentiviral vector-based gene delivery system.
Directors
- Roch Doliveux NEC (65)
- Stuart Henderson VCH
- Stuart Paynter CFO
- Nick Page COO
- Helen Stephenson-Ellis CHO
- James Miskin CTO
- Kyriacos Mitrophanous CSO
- Natalie Walter GCN
- Jason Slingsby OTH
- Robert Ghenchev NED
- Michael Hayden NED (69)
- Dame Kay Davies NID
- Catherine Moukheibir NID (62)
- Heather Preston NID (55)
- Siyamak Rasty NID
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- September 20th, 1996
- Public Since
- November 15th, 1996
- No. of Employees
- 834
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- London Stock Exchange
- Shares in Issue
- 105,997,300
- Address
- Windrush Court, Transport Way, OXFORD, OX4 6LT
- Web
- https://www.oxb.com/
- Phone
- +44 1865783000
- Contact
- Sophia Bolhassan
- Auditors
- KPMG LLP
Latest News for OXB
Upcoming Events for OXB
Oxford BioMedica PLC Annual Shareholders Meeting
Half Year 2025 Oxford Biomedica PLC Earnings Release
Similar to OXB
4Basebio
London Stock Exchange
Allergy Therapeutics
London Stock Exchange
Arecor Therapeutics
London Stock Exchange
Avacta
London Stock Exchange
Batm Advanced Communications
London Stock Exchange
FAQ
As of Today at 22:31 UTC, shares in Oxford BioMedica are trading at 299.00p. This share price information is delayed by 15 minutes.
Shares in Oxford BioMedica last closed at 299.00p and the price had moved by +57.04% over the past 365 days. In terms of relative price strength the Oxford BioMedica share price has outperformed the FTSE All Share Index by +50.87% over the past year.
The overall consensus recommendation for Oxford BioMedica is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreOxford BioMedica does not currently pay a dividend.
Oxford BioMedica does not currently pay a dividend.
Oxford BioMedica does not currently pay a dividend.
To buy shares in Oxford BioMedica you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 299.00p, shares in Oxford BioMedica had a market capitalisation of £316.93m.
Here are the trading details for Oxford BioMedica:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: OXB
Based on an overall assessment of its quality, value and momentum Oxford BioMedica is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Oxford BioMedica is 544.43p. That is 82.08% above the last closing price of 299.00p.
Analysts covering Oxford BioMedica currently have a consensus Earnings Per Share (EPS) forecast of -£0.33 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Oxford BioMedica. Over the past six months, its share price has underperformed the FTSE All Share Index by -23.18%.
As of the last closing price of 299.00p, shares in Oxford BioMedica were trading -18.94% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Oxford BioMedica PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at 299.00p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Oxford BioMedica's management team is headed by:
- Roch Doliveux - NEC
- Stuart Henderson - VCH
- Stuart Paynter - CFO
- Nick Page - COO
- Helen Stephenson-Ellis - CHO
- James Miskin - CTO
- Kyriacos Mitrophanous - CSO
- Natalie Walter - GCN
- Jason Slingsby - OTH
- Robert Ghenchev - NED
- Michael Hayden - NED
- Dame Kay Davies - NID
- Catherine Moukheibir - NID
- Heather Preston - NID
- Siyamak Rasty - NID